Purpose: Although lung recruitment manoeuvres (RMs) during mechanical ventilation may reduce atelectasis, the optimal recruitment strategy for patients undergoing thoracic surgery remains unknown. Our study was to investigate whether ultrasound-guided lung RMs is superior to conventional RMs in reducing incidence of perioperative atelectasis during thoracic surgery with one-lung ventilation. Methods: We conducted a randomised controlled trial from August 2022 to September 2022. Sixty patients scheduled for video-assisted thoracoscopic surgery (VATS) under general anaesthesia were enrolled. Subjects were randomly divided into the ultrasound-guided RMs group (manual inflation guided by lung ultrasound) or conventional RMs group (manual inflation with 30 cmH 2 O pressure). Ultrasound were performed at three predefined time points (1 min after anaesthetic induction; after RMs at the end of surgery; before discharge from postanesthesia care unit [PACU]). The primary outcome was lung ultrasound score before discharge from the PACU after extubation. Results: In the early postoperative period, lung aeration deteriorated in both groups even after lung RMs. However, ultrasound-guided lung RMs had significantly lower lung ultrasound scores when compared with conventional RMs in bilateral lungs (2.0 [0.8–4.0] vs. 8.0 [3.8–10.3], P < 0.01) at the end of surgery, which remained before patients discharged from the PACU. Accordingly, the lower incidence of atelectasis was found in ultrasound-guided RMs group than in conventional RMs group (7% vs. 53%; P < 0.01) at the end of surgery. Conclusion: Ultrasound-guided RMs is superior to conventional RMs in improving lung aeration and reducing lung atelectasis at early postoperative period in patients undergoing VATS. Trial registration: The study protocol was approved by the Institutional Review Board of the Fudan University Shanghai Cancer Center (No.220825810; date of approval: August 5, 2022) and registered on Chinese Clinical Trial Registry (number: ChiCTR2200062761).

OBJECTIVE:Anesthesia is correlated with the prognosis of cancer surgery. However, evidence from prospective studies focusing on breast cancer is currently limited. This systematic review aimed to investigate the effect of anesthesia-related interventions on oncological outcomes following breast cancer surgery in prospective studies.METHODS:Literature searches were performed from inception to June. 2023 in the Pubmed, Web of Science, Embase, and ClinicalTrials databases. The main inclusion criteria comprised a minimum of one-year follow-up duration, with oncological outcomes as endpoints. Anesthesia-related interventions encompassed, but were not limited to, type of anesthesia, anesthetics, and analgesics. The risk of bias was assessed using the Cochrane Risk of Bias Tool.RESULTS:A total of 9 studies were included. Anesthesia-related interventions included paravertebral nerve block (3), pectoral nerve block (1), sevoflurane (2), ketorolac (2), and infiltration of lidocaine (1). Cancer recurrence, metastasis, disease-free survival, or (and) overall survival were assessed. Among all included studies, only infiltration of lidocaine was found to prolong disease-free survival and overall survival.CONCLUSION:Regional anesthesia and propofol did not improve oncological outcomes following breast cancer surgery. The anti-tumorigenic effect of ketorolac warrants future studies with larger sample sizes. Perioperative infiltration of lidocaine around the tumor may be a promising anti-tumorigenic intervention that can prolong overall survival in patients with early breast cancer.

Tranexamic acid reduces blood loss and allogeneic transfusion requirements in various surgical procedures. The role of tranexamic acid during cytoreductive procedures in advanced ovarian cancer is not clear. This was a single center randomized, controlled, three-armed clinical trial. A total of 150 ovarian cancer patients undergoing cytoreductive surgery were recruited and assigned to three groups ( n  = 50/group): the control group (normal saline), low-dose group (10 mg/kg bolus + 1 mg/kg continuous infusion of tranexamic acid), and high-dose group (20 mg/kg bolus + 5 mg/kg continuous infusion of tranexamic acid). The primary endpoint was intraoperative blood loss volume and total blood loss volume, and secondary endpoints included intraoperative blood transfusion volumes, vasoactive agent consumption, admission into the intensive care unit, and incidence of postoperative complications within postoperative 30 days. The study was registered at ClinicalTrials.gov ID: NCT04360629. The patients in the high-dose group had less intraoperative (median [IQR]: 625.3 mL [343.5–1210.5]) and total blood loss volume (748.9 mL [292.2–1650.2]) than those in the control group (1015.5 mL [679.4–1015.5], p  = 0.012; and 1700.7 mL [458.7–2419.8], p  = 0.004, respectively). In contrast, the intraoperative (992.5 mL [539.0–1404.0], p  = 0.874) and total blood loss volume (1025.0 mL [381.8–1819.9], p  = 0.113) was not significantly reduced in the low-dose group when compared with the control group. Correspondingly, the relative risk of blood transfusion (RR [95% CI], 0.405 [0.180–0.909], p  = 0.028) was reduced in the high-dose group and required less intraoperative noradrenaline (881.0 ± 438.3 mg) to maintain stable hemodynamics than the control group (1548.0 ± 349.8 mg, p  = 0.001). Furthermore, compared with the control group, the two tranexamic acid groups had decreased intensive care unit admission rates ( p  = 0.016) without increasing the incidence of postoperative seizure, acute kidney injury, and thromboembolism. High-dose tranexamic acid is more effective in reducing blood loss and blood transfusion without increasing the risk of postoperative complications. The high-dose regime tended to have a better risk–benefit profile.

INTRODUCTION:Tranexamic acid reduces blood loss and allogeneic transfusion requirements in various surgical procedures. The role of tranexamic acid during cytoreductive procedures in advanced ovarian cancer is not clear. MATERIAL AND METHODS:This was a single center randomized, controlled, three-armed clinical trial. A total of 150 ovarian cancer patients undergoing cytoreductive surgery were recruited and assigned to three groups (n = 50/group): the control group (normal saline), low-dose group (10 mg/kg bolus + 1 mg/kg continuous infusion of tranexamic acid), and high-dose group (20 mg/kg bolus + 5 mg/kg continuous infusion of tranexamic acid). The primary endpoint was intraoperative blood loss volume and total blood loss volume, and secondary endpoints included intraoperative blood transfusion volumes, vasoactive agent consumption, admission into the intensive care unit, and incidence of postoperative complications within postoperative 30 days. The study was registered at ClinicalTrials.gov ID: NCT04360629. RESULTS:The patients in the high-dose group had less intraoperative (median [IQR]: 625.3 mL [343.5-1210.5]) and total blood loss volume (748.9 mL [292.2-1650.2]) than those in the control group (1015.5 mL [679.4-1015.5], p = 0.012; and 1700.7 mL [458.7-2419.8], p = 0.004, respectively). In contrast, the intraoperative (992.5 mL [539.0-1404.0], p = 0.874) and total blood loss volume (1025.0 mL [381.8-1819.9], p = 0.113) was not significantly reduced in the low-dose group when compared with the control group. Correspondingly, the relative risk of blood transfusion (RR [95% CI], 0.405 [0.180-0.909], p = 0.028) was reduced in the high-dose group and required less intraoperative noradrenaline (881.0 ± 438.3 mg) to maintain stable hemodynamics than the control group (1548.0 ± 349.8 mg, p = 0.001). Furthermore, compared with the control group, the two tranexamic acid groups had decreased intensive care unit admission rates (p = 0.016) without increasing the incidence of postoperative seizure, acute kidney injury, and thromboembolism. CONCLUSIONS:High-dose tranexamic acid is more effective in reducing blood loss and blood transfusion without increasing the risk of postoperative complications. The high-dose regime tended to have a better risk-benefit profile.

A 44-year-old male presented to our emergency department with a chief complaint of a hard plastic bottleneck strangulating around the base of his penis for 3 hours. The patient inserted his penis into a bath lotion bottle for masturbation, of which the bottleneck was approximately 1.8 centimeters in diameter. Due to penis swelling, congestion, and pain, the patient found that the penis could not be pulled out after 2 hours. He tried to remove it completely by himself but failed. As the patient was concerned about penile necrosis, he sought emergency care at our hospital. Physical examination revealed that the patient had a hard plastic bottleneck and part of the bath lotion bottle around the proximal phallus. The phallus was severely edematous, purplish red, and had weak arterial pulsation (Fig. 1).

目的:探讨芳香精油疗法治疗Ⅲ型慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)的安全性和有效性.方法:采用随机抽样法,选取2018年1月—2019年12月在复旦大学附属上海市第五人民医院泌尿外科就诊的Ⅲ型CP/CPPS的患者70例为研究对象,采用随机数字表法将其分为试验组和对照组,两组各35例.对照组在常规治疗的基础上采用甘油按摩腹股沟淋巴结和八髎穴,试验组采用自主研发的前列腺炎专用芳香精油进行按摩,每日2次,持续4周.比较干预前后两组患者美国国立卫生研究院慢性前列腺炎症状评分(NIH-CPSI)、国际前列腺症状评分(IPSS)、焦虑自评量表(SAS)评分和国际勃起功能指数(IIEF-5)及前列腺液实验室检查指标的变化情况.结果:共67例患者完成了全部治疗,均未发生不良反应.治疗4周后,试验组与对照组在疼痛、排尿、生活质量、NIH-CPSI总分、IPSS、SAS、1IEF-5评分、临床实验室检查评分等方面比较差异均无统计学意义(P＞0.05),但试验组疼痛和不适范围较对照组明显减少(P＜0.01),焦虑程度也显著下降(P＜0.01).结论:芳香精油疗法治疗可减轻CP/CPPS患者的疼痛和不适,有效缓解焦虑.

OBJECTIVE:To study the effects of 1470 nm semiconductor laser enucleation of the prostate (SCLEP) and transurethral plasma electrotomy (TUPE) on erectile function and pelvic floor muscle strength in BPH patients.METHODS:We retrospectively analyzed the clinical data on 72 cases of BPH treated in our hospital from July 2017 to July 2019 by TUPE (group A, n = 36) or 1470 nm SCLEP (group B, n = 36). We observed and compared the postoperative penile erectile function, retrograde ejaculation and pelvic floor muscle strength between the two groups of patients.RESULTS:Compared with group A, group B showed a significantly higher IIEF-5 score (19.43 ± 1.61 vs 21.15 ± 1.32, P < 0.05) and pelvic floor muscle strength (electromyographic ［EMG］ value) during rapid contraction (36.36 ± 1.38 vs 43.53 ± 2.04, P < 0.05), continuous contraction (34.27 ± 1.63 vs 39.46 ± 1.48, P < 0.05) and endurance test (35.24 ± 1.57 vs 38.19 ± 1.67, P < 0.05), but lower incidence rates of ED and retrograde ejaculation.CONCLUSIONS:Compared with TUPE, 1470 nm SCLEP affects less the erectile function and pelvic floor muscle strength of BPH patients.

OBJECTIVE To evaluate the efficacy and safety of 1470-nm Diode Laser Enucleation of the Prostate (DiLEP) in patients with benign prostatic hyperplasia continuously receiving oral anticoagulants or antiplatelet drugs. METHODS From January 2016 to June 2017, 144 patients were submitted to 1470-nm DiLEP, including 49 (34.0%) continuously administered anticoagulants or antiplatelet drugs per os due to cardiac and/or cerebrovascular diseases (group A), while 95 (66.0%) were not (group B). Evaluation was performed preoperatively, and at postoperative 3, 6, and 12 months, respectively. Patient baseline features, operative data, perioperative complications, and postsurgical outcomes were assessed. RESULTS Both groups had comparable preoperative parameters, except age (77.3 +/- 7.5 vs 73.2 (+/-) 8.8 years, P = .007). Meanwhile, surgical time, sodium decrease, catheterization duration, and hospital stay markedly differed between the 2 groups. In comparison with group B, group A patients had statistically higher blood loss (14.9 +/- 7.3 g/L vs 10.2 +/- 7.0 g/L, P < .001) and increased bladder irrigation time (21.1 +/- 10.9 hours vs 16.1 +/- 9.0 hours, P = .004). One case required blood transfusion in group A, because of moderate anemia preoperatively. Both groups showed similar blood transfusion and complication rates. International Prostate Symptom Score, quality of life score, maximum flow rate, and postvoid residual were markedly improved in both groups at 3-, 6-, and 12-month follow-up postoperatively compared with baseline values. However, no statistically significant differences were observed between the 2 groups in various assessment parameters at follow-up (P > .05). CONCLUSION These findings demonstrated that 1470-nm DiLEP is efficient and safe in benign prostatic hyperplasia cases receiving continuous oral anticoagulant or antiplatelet drugs. Anticoagulation therapy did not significantly influence the results and complication rates. (C) 2020 Elsevier Inc.

目的 探讨生物反馈联合电刺激治疗对1470nm半导体激光前列腺汽化剜除术(DiLEP)患者术后下尿路症状(LUTS)的影响.方法 本研究为非随机对照试验,选取2016年1月—2018年9月我院收治并实施DiLEP术的126例良性前列腺增生的患者作为研究对象,分为观察组63例、对照组63例.观察组从术前2周开始实施生物反馈联合电刺激治疗至术后12周;对照组实施前列腺剜除术后单纯盆底肌肉训练.分析两组患者术前、术后LUTS症状的改善情况,比较国际前列腺症状评分(IPSS)、生活质量评分(QoL)、最大尿流率(Qmax)和膀胱残余尿量(PⅤR)的变化.结果 观察组术后4周和术后12周的LUTS症状改善情况、IPSS评分、生活质量评分(QoL)、最大尿流率(Qmax)和膀胱残余尿量(PⅤR)均优于对照组,差异有统计学意义(P<0.05).结论 生物反馈电刺激治疗可以改善早期DiLEP术后LUTS症状,加速1470 nm半导体激光前列腺剜除术患者的术后康复,提高患者的生活质量,值得临床推广.

目的 探讨经尿道1 470 nm半导体激光前列腺汽化切除术联合腹腔镜下膀胱憩室切除术同期治疗前列腺增生合并膀胱憩室的可行性和优越性.方法 回顾性地分析自2017年8月至2018年2月我科收治的应用经尿道1 470 nm半导体激光前列腺汽化切除术联合腹腔镜下膀胱憩室切除术同期治疗前列腺增生合并膀胱憩室6例患者的临床资料.结果 6例手术均成功完成,无中转开放手术,平均手术时间为(206.3±19.54) (185～240)min,术中出血量平均为(69.2±18.01)(50～100)mL,术后平均膀胱冲洗时间为(15.8±5.67)(8～22)h,平均住院时间为(8.5±1.05)(7～10)d.术后3个月随访患者排尿症状明显改善,平均最大尿流率为(19.9±3.06)(16.8～25.2)mL/s,平均残余尿为(19.2±8.01)(10～30)mL,术后无相关并发症发生.结论 经尿道1 470 nm半导体激光前列腺汽化切除术联合腹腔镜下膀胱憩室切除术同期治疗前列腺增生合并膀胱憩室是一种安全、可行的手术方法,由于其手术创伤小、出血少、患者恢复快,具有一定的优越性.

目的 评价生物反馈联合电刺激治疗中老年女性压力性尿失禁的效果.方法 采用便利抽样法选取2015年9月1日到2017年12月31日在复旦大学附属上海市第五人民医院就诊的168例中老年女性压力性尿失禁患者分成两组.观察组84例给予生物反馈联合电刺激锻炼盆底肌,每周2次,每次30 min;对照组84例给予单纯Kegel锻炼盆底肌.比较两组患者治疗前及治疗后4周、8周的排尿相关指标:3d漏尿次数、1h尿垫试验漏尿量、尿失禁问卷简表(ICI-Q-SF)、盆底肌肉功能Glazer评估测试,评价两种方法对于盆底肌肉功能训练的效果.结果 观察组治疗后4周及8周的排尿相关指标同对照组相比,尿失禁问卷简表(ICI-Q-SF)得分(5.8±2.4 vs.7.9±2.7,P＜0.01;7.2±2.9vs.8.9±3.1,P＜0.01)、1h尿垫试验漏尿量[(4.87±1.92)gvs.(7.79±2.08)g,P＜0.05;(6.42±0.86)g vs.(9.43±0.94)g,P＜0.05)]和3d漏尿次数[(2.48±2.35)次vs.(4.86±2.17)次,P＜0.05;(3.15±1.26)次vs.(5.55±1.63)次,P＜0.05]等结果均优于对照组,差异有统计学意义.结论 盆底生物反馈联合电刺激治疗中老年女性压力性尿失禁优于单纯Kegel锻炼方法,值得临床推广.

Funding information Natural Science Foundation of Shanghai, Grant/Award Number: 18ZR1429800; Shanghai Rising‐Star Program, Grant/Award Number: 17QA1403700; The Fifth People`s Hospital of Shanghai, Fudan University, Grant/ Award Number: 2018WYZD02 Abstract Background: POH1, a member of the JAMM domain containing deubiquitinases, functions in malignant progression of certain types of cancer. However, the role of POH1 in prostate cancer (PCa) remains unclear. Methods: We performed RNA interference against the JAMM members in PC3 cells and analyzed cell proliferation. POH1 knockdown was established to evaluate the effects of POH1 on cell growth in vitro and in vivo. RNA‐sequencing was utilized to explore the molecular details underlying the biological function of POH1 in PCa. The expression of POH1 in PCa tissues was detected by immunohistochemistry. The POH1 inhibitor capzimin was evaluated to explore whether pharmacologically inhibiting POH1 significantly affected PCa cell proliferation alone or enhanced the inhibitory efficacy of docetaxel and androgen deprivation. Results: Functional analyses identified POH1 as a JAMM deubiquitinase that is required for PCa proliferation. Importantly, expression of POH1 was higher in human PCa tissues (PCas) than that in normal prostate tissues, and a positive correlation was detected between elevated POH1 expression and higher pathological grades in PCas. In vivo experiments further demonstrated that depleting POH1 significantly suppressed the growth of PCa cell xenografts. POH1 deficiency profoundly inhibited the expression of a set of genes involving the cell cycle and caused G0/G1 phase arrest. Furthermore, the POH1 inhibitor capzimin phenotypically recapitulated the effects of POH1 knockdown and improved the efficacy of docetaxel and androgen deprivation in PCa cells. Conclusions: POH1 was overexpressed in PCas and was correlated with pathological grades in human PCas. Inhibiting POH1 by gene silencing or pharmacological inhibition with capzimin suppressed PCa cell growth. Exploring the inhibition of

目的 比较使用封堵取石导管联合输尿管镜钬激光碎石术治疗输尿管上段结石的临床效果和安全性.方法 输尿管上段结石病人120例,随机分为两组,每组各60例,封堵器组采用封堵取石导管,无封堵器组不使用任何封堵装置组,行输尿管镜下钬激光碎石术,观察两组手术时间、碎石率及并发症发生情况.结果 封堵器组一期碎石成功率为93.3％,无封堵器组为78.3％,封堵器组术后住院时间为(2.5±0.4)天,无封堵器组(3.7±0.6)天;封堵器组术后随访无石率为96.7％,无封堵器组为86.7％,两组比较差异均有统计学意义(P<0.05).两组手术并发症比较差异无统计学意义(P>0.05).结论 输尿管镜下使用封堵取石导管联合钬激光碎石,可减少输尿管上段结石的漂移,提高结石清除率,缩短住院时间.

Objective To investigate the therapeutic effects of first phase renal puncture and drainage guided by B ultrasound and second phase percutaneous nephrolithotomy(PCNL) in the treatment of urinary calculi complicated with pyonephrosis. Methods From January 2014 to April 2018, 28 patients with upper ureteral segment and kidney calculi complicated with pyonephrosis were collected. All patients received the pyonephrosis puncture under B ultrasound. After the inflammation was controlled and the clinical situation improved, the second phase was treated by PCNL. During the operation, routine in dwelling ureteral stent drainage and renal fistula wereperformed. The outcomes of the operation were observed. Results A total of 28 cases were successfully punctured, the obstruction was relieved and the inflammation was controlled. Additionally, the second phase of PCNL surgery was successful, and there were no significant stone residues after PCNL. There were no complications such as severe systemic inflammatory response syndrome and severe hemorrhage. After 3 to 12 months of follow-up, renal function was restored to varying degrees, and there were no renal failure patients who needednephrectomy.Conclusions Early diagnosis of urinary calculi complicated with pyonephrosis is the key to successful treatment. Active and effective B ultrasound-guided renal puncture and drainage, drainage of pus, and removal of urinary obstruction can improve the safety of the second phase of PCNL, and thus it attaches great importance to the treatment of pyonephrosis.

目的 评估国产醋酸去氨加压素片与原研药物治疗女性夜间多尿症的疗效及安全性.方法 96例女性夜间多尿症患者被随机分为2组,试验组给予国产醋酸去氨加压素片,每日睡前服用0.1 mg,共治疗8周.对照组给予进口原研醋酸去氨加压素片,剂量和疗程同试验组.治疗8周后,评价两组夜尿次数、夜尿量、夜间多尿指数、24 h排尿次数、24 h尿量、第一次觉醒睡眠时间等指标和治疗后肝肾功能异常率、血钠值异常率和残余尿量异常率.结果 经8周治疗,两组患者主要结局指标夜尿次数、夜尿量、夜间多尿指数及24 h排尿总次数、24 h尿量、第一次觉醒睡眠时间比较,差异均无统计学意义(P均＞0.05).组内比较:两组夜尿次数、夜尿量、夜间多尿指数、治疗前后比较差异均有统计学意义(P均＜0.05).以50岁为界做亚组分析,在不同亚组人群中,两种药物治疗效果无统计学差异(P＞0.05).两组均未发生明显不良反应.结论 国产醋酸去氨加压素片和进口原研药物治疗女性夜间多尿症近期疗效、安全性无统计学差异,可作为治疗女性夜间多尿症有效可选药物.

目的 探讨经尿道1 470 nm半导体激光前列腺剜除术(DiLEP)治疗体积＞80 mL的良性前列腺增生症(BPH)患者的临床疗效及安全性.方法 2016年1月至2018年1月复旦大学附属上海市第五人民医院为74例大体积BPH患者实施DiLEP术,收集这些患者临床资料进行回顾性分析,观察手术时间、膀胱持续冲洗时间、留置导尿时间、住院天数、术后血红蛋白及血清钠离子变化情况、手术并发症.术后3个月及6个月随访患者,评估膀胱残余尿量(PVR)、最大尿流率(Qmax)、国际前列腺症状评分(IPSS)、及生活质量评分(QoL)改善情况.结果 74例手术均成功完成,平均手术时间(104.9±25.1)min,平均膀胱冲洗时间(22.1±9.8)h,平均导尿时间(3.2±1.1)d,平均住院天数5～11(8.3±1.1)d,术后血红蛋白及血清钠离子浓度无明显下降.术后3个月、6个月患者PVR、Qmax、IPSS、QoL较术前明显改善(P＜0.05).术中无中转开放及TURP,无直肠、膀胱穿孔,无电切综合征(TURS),无明显出血,术后无输血术,无永久性尿失禁.结论 经尿道1 470 nm半导体激光前列腺剜除术治疗大体积前列腺增生疗效显著且安全性高,值得临床进一步推广及应用.

输尿管结石是泌尿外科最为常见的疾病,随着微创腔内泌尿外科技术及设备的发展,经输尿管镜碎石术治疗输尿管结石的临床应用日趋普及,现如今气压弹道碎石术在基层医院已经广泛开展.相对于气压弹道碎石术,钬激光碎石术有其一定的优势,然而由于钬激光设备费用较昂贵,限制其在基层医院的普及使用.

Objective To establish a method of isolation and culture of the rat skeletal muscle satellite cells.To investigate the feasibility of in vitro constructing cell-polyglycolic acid (PGA) complex from skeletal muscle satellite cells seeded on PGA.Methods Primary skeletal muscle satellite cells were harvested by enzyme.After series culture and expansion in vitro,Immunohistochemistry staining was carried out to detect the immunophenotypes of skeletal muscle satellite cells.After skeletal muscle satellite cells were transfected by lentiviral vector carrying green fluorescent protein (GFP),skeletal muscle cell-PGA complex was constructed by seeding transfected skeletal muscle satellite cells on PGA fibers.The cell-PGA complex was examined by light microscope and scanning electron microscope (SEM).Results Immunohistochemistry staining showed that skeletal muscle satellite cells expressed Desmin and Vimentin.Microscopic observation showed the production of rich extracellular matrices by transfected skeletal muscle satellite cells was observed in the cell-scaffold construct,SEM observations showed that the secreted matrices filled the space between the PGA fibers.Conclusion Transfected skeletal muscle satellite cells have good biocompatibility with PGA.Imaging with expression of GFP facilitates the research on skeletal muscle satellite cells application in tissue engineering in vivo.

总结经尿道1470nm半导体激光前列腺汽化剜除术(DiLEP)治疗高龄高危复杂性良性前列腺增生症(BPH)患者的手术护理配合.术前充分了解患者的身心情况,术中完善的物品准备、熟练的手术配合和紧密的相互协作,术后严密观察患者生命体征及膀胱冲洗液的颜色等.80例手术均获成功.无电切综合征(TURS)、无术后输血、无永久性尿失禁、无尿道狭窄等并发症.结论:良好的围手术期护理可保证手术成功、促进患者早日康复.